Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GEORGE J CHANG and JOHN M SKIBBER.
GEORGE J CHANG
Connection Strength
5.239
JOHN M SKIBBER
  1. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer. 2009 Dec 01; 115(23):5432-40.
    View in: PubMed
    Score: 0.363
  2. Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation? Dis Colon Rectum. 2019 10; 62(10):1158-1166.
    View in: PubMed
    Score: 0.180
  3. Assessment of Ileostomy Output Using Telemedicine: A Feasibility Trial. Dis Colon Rectum. 2018 Jan; 61(1):77-83.
    View in: PubMed
    Score: 0.159
  4. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2631-2638.
    View in: PubMed
    Score: 0.154
  5. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):455-464.
    View in: PubMed
    Score: 0.151
  6. Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer. Cancer. 2017 04 01; 123(7):1124-1133.
    View in: PubMed
    Score: 0.144
  7. Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015 Mar 01; 150(3):245-51.
    View in: PubMed
    Score: 0.131
  8. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015 Jan; 150(1):17-22.
    View in: PubMed
    Score: 0.129
  9. Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol. 2014 Sep 20; 32(27):2967-74.
    View in: PubMed
    Score: 0.127
  10. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014 Apr 15; 120(8):1162-70.
    View in: PubMed
    Score: 0.121
  11. Impact of ileostomy-related complications on the multidisciplinary treatment of rectal cancer. Ann Surg Oncol. 2014 Feb; 21(2):507-12.
    View in: PubMed
    Score: 0.118
  12. A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg. 2013 Aug; 148(8):769-77.
    View in: PubMed
    Score: 0.117
  13. An individualized conditional survival calculator for patients with rectal cancer. Dis Colon Rectum. 2013 May; 56(5):551-9.
    View in: PubMed
    Score: 0.115
  14. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2013 Feb; 56(2):135-41.
    View in: PubMed
    Score: 0.113
  15. Multimodality salvage of recurrent disease after local excision for rectal cancer. Dis Colon Rectum. 2012 Dec; 55(12):1213-9.
    View in: PubMed
    Score: 0.112
  16. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20; 30(15):1770-6.
    View in: PubMed
    Score: 0.107
  17. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012 Sep; 19(9):2814-21.
    View in: PubMed
    Score: 0.107
  18. Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation. Dis Colon Rectum. 2012 Apr; 55(4):371-7.
    View in: PubMed
    Score: 0.107
  19. Reverse-hybrid robotic mesorectal excision for rectal cancer. Dis Colon Rectum. 2012 Feb; 55(2):228-33.
    View in: PubMed
    Score: 0.106
  20. Prognostic value of quality of life and pain in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2011 Apr; 18(4):989-96.
    View in: PubMed
    Score: 0.097
  21. Multidisciplinary approach to recurrent/unresectable rectal cancer: how to prepare for the extent of resection. Surg Oncol Clin N Am. 2010 Oct; 19(4):847-59.
    View in: PubMed
    Score: 0.096
  22. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010 Nov; 17(11):2863-9.
    View in: PubMed
    Score: 0.094
  23. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol. 2009 Dec 10; 27(35):5938-43.
    View in: PubMed
    Score: 0.090
  24. A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum. 2009 Aug; 52(8):1375-80.
    View in: PubMed
    Score: 0.089
  25. Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. Ann Surg Oncol. 2008 Jan; 15(1):46-51.
    View in: PubMed
    Score: 0.079
  26. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg. 2007 Aug; 246(2):215-21.
    View in: PubMed
    Score: 0.077
  27. Barriers to rehabilitation of colorectal cancer patients. J Surg Oncol. 2007 Apr 01; 95(5):400-8.
    View in: PubMed
    Score: 0.075
  28. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007 Mar 21; 99(6):433-41.
    View in: PubMed
    Score: 0.075
  29. Surgical implications of colorectal cancer genetics. Surg Oncol Clin N Am. 2006 Jan; 15(1):51-66, vi.
    View in: PubMed
    Score: 0.069
  30. Early Postoperative Prediction of Complications and Readmission After Colorectal Cancer Surgery Using an Artificial Neural Network. Dis Colon Rectum. 2024 Jul 03.
    View in: PubMed
    Score: 0.062
  31. ASO Visual Abstract: Para-aortic Lymph Node Dissection for Colorectal Cancer-Predicting Pathologic Lymph Node Positivity and Optimizing Outcomes. Ann Surg Oncol. 2024 Jun 29.
    View in: PubMed
    Score: 0.062
  32. Para-aortic Lymph Node Dissection for Colorectal Cancer: Predicting Pathologic Lymph Node Positivity and Optimizing Outcomes. Ann Surg Oncol. 2024 Jun 05.
    View in: PubMed
    Score: 0.062
  33. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 06; 22(2 D).
    View in: PubMed
    Score: 0.062
  34. Total Neoadjuvant Therapy for Rectal Cancer: Which Regimens to Use? Cancers (Basel). 2024 May 31; 16(11).
    View in: PubMed
    Score: 0.062
  35. The current multidisciplinary management of rectal cancer. Ann Gastroenterol Surg. 2024 May; 8(3):394-400.
    View in: PubMed
    Score: 0.061
  36. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel). 2023 Mar 10; 15(6).
    View in: PubMed
    Score: 0.057
  37. Impact of cumulative operative time on postoperative complication risk in simultaneous resections of colorectal liver metastases and primary tumors. HPB (Oxford). 2023 03; 25(3):347-352.
    View in: PubMed
    Score: 0.056
  38. A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. J Gastrointest Oncol. 2022 Dec; 13(6):2938-2950.
    View in: PubMed
    Score: 0.056
  39. Germline Cancer Risk Profiles of Patients With Young-Onset Colorectal Cancer: Findings From a Prospective Universal Germline Testing and Telegenetics Program. Dis Colon Rectum. 2023 04 01; 66(4):531-542.
    View in: PubMed
    Score: 0.053
  40. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.
    View in: PubMed
    Score: 0.053
  41. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37.
    View in: PubMed
    Score: 0.052
  42. Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstet Med. 2022 Jun; 15(2):118-124.
    View in: PubMed
    Score: 0.051
  43. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045.
    View in: PubMed
    Score: 0.050
  44. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer. 2019 12; 18(4):301-306.
    View in: PubMed
    Score: 0.044
  45. Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600.
    View in: PubMed
    Score: 0.041
  46. Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. Am J Clin Oncol. 2018 07; 41(7):632-637.
    View in: PubMed
    Score: 0.041
  47. Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997.
    View in: PubMed
    Score: 0.040
  48. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560.
    View in: PubMed
    Score: 0.040
  49. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Jun; 40(3):277-282.
    View in: PubMed
    Score: 0.038
  50. Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017 Apr; 40(2):163-166.
    View in: PubMed
    Score: 0.038
  51. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151.
    View in: PubMed
    Score: 0.037
  52. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol. 2016 09 01; 34(25):3039-46.
    View in: PubMed
    Score: 0.036
  53. A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. J Natl Compr Canc Netw. 2015 Jul; 13(7):865-72.
    View in: PubMed
    Score: 0.033
  54. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015 May; 150(5):402-9.
    View in: PubMed
    Score: 0.033
  55. Functional deficits and symptoms of long-term survivors of colorectal cancer treated by multimodality therapy differ by age at diagnosis. J Gastrointest Surg. 2015 Jan; 19(1):180-8; discussio 188.
    View in: PubMed
    Score: 0.032
  56. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol. 2014 Jun; 109(7):652-8.
    View in: PubMed
    Score: 0.030
  57. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.
    View in: PubMed
    Score: 0.030
  58. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
    View in: PubMed
    Score: 0.030
  59. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75.
    View in: PubMed
    Score: 0.029
  60. Metformin use and improved response to therapy in rectal cancer. Cancer Med. 2013 Feb; 2(1):99-107.
    View in: PubMed
    Score: 0.028
  61. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol. 2013 Feb; 20(2):482-90.
    View in: PubMed
    Score: 0.027
  62. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics. 2012 Mar-Apr; 32(2):389-409.
    View in: PubMed
    Score: 0.027
  63. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3713-22.
    View in: PubMed
    Score: 0.025
  64. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg. 2010 Feb; 251(2):261-4.
    View in: PubMed
    Score: 0.023
  65. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):60-5.
    View in: PubMed
    Score: 0.022
  66. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
    View in: PubMed
    Score: 0.022
  67. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):818-23.
    View in: PubMed
    Score: 0.021
  68. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1175-80.
    View in: PubMed
    Score: 0.020
  69. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007 May 01; 109(9):1750-5.
    View in: PubMed
    Score: 0.019
  70. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007 Jun; 14(6):1870-7.
    View in: PubMed
    Score: 0.019
  71. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):794-800.
    View in: PubMed
    Score: 0.019
  72. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007 Mar; 1(2):44-8.
    View in: PubMed
    Score: 0.019
  73. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol. 2007 Feb; 14(2):478-83.
    View in: PubMed
    Score: 0.018
  74. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71.
    View in: PubMed
    Score: 0.018
  75. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83.
    View in: PubMed
    Score: 0.018
  76. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.